IJCEP Copyright © 2007-All rights reserved.
Int J Clin Exp Pathol 2013;6(8):1538-1548

Original Article
DNA microarray reveals different pathways responding to paclitaxel and docetaxel in
non-small cell lung cancer cell line

Chun-Li Che, Yi-Mei Zhang, Hai-Hong Zhang, Yu-Lan Sang, Ben Lu, Fu-Shi Dong, Li-Juan Zhang, Fu-Zhen Lv

Department of respiratory medicine, First Clinical Medical College affiliated to Harbin Medical University, Harbin, China; Department of
rheumatism and immunology, First Clinical Medical College affiliated to Harbin Medical University, Harbin, China; Department of respiratory
medicine, Second Clinical Medical College affiliated to Harbin Medical University, Harbin, China

Received June 20, 2013; Accepted July 5, 2013; Epub July 15, 2013; Published August 1, 2013

Abstract: The wide use of paclitaxel and docetaxel in NSCLC clinical treatment makes it necessary to find biomarkers for identifying patients
who can benefit from paclitaxel or docetaxel. In present study, NCI-H460, a NSCLC cell line with different sensitivity to paclitaxel and docetaxel,
was applied to DNA microarray expression profiling analysis at different time points of lower dose treatment with paclitaxel or docetaxel. And
the complex signaling pathways regulating the drug response were identified, and several novel sensitivity-realted markers were
biocomputated.The dynamic changes of responding genes showed that paclitaxel effect is acute but that of docetaxel is durable at least for 48
hours in NCI-H460 cells. Functional annotation of the genes with altered expression showed that genes/pathways responding to these two
drugs were dramatically different. Gene expression changes induced by paclitaxel treatment were mainly enriched in actin cytoskeleton
(ACTC1, MYL2 and MYH2), tyrosine-protein kinases (ERRB4, KIT and TIE1) and focal adhesion pathway (MYL2, IGF1 and FLT1), while the
expression alterations responding to docetaxel were highly co-related to cell surface receptor linked signal transduction (SHH, DRD5 and
ADM2), cytokine-cytokine receptor interaction (IL1A and IL6) and cell cycleregulation (CCNB1, CCNE2 and PCNA). Moreover, we also confirmed
some different expression patterns with real time PCR. Our study will provide the potential biomarkers for paclitaxel and docetaxel-selection
therapy in clinical application. (IJCEP1306019).

Keywords: Non-small cell lung cancer, paclitaxel, docetaxel, microarray

Address correspondence to: Dr. Fu-Zhen Lv,  Department of respiratory medicine, Second Clinical Medical College affiliated to Harbin Medical
University, Harbin, China. E-mail: fuzhenlv_harbin@163.com